文献速递妇科肿瘤

IA-C期任何级别未成熟畸胎瘤可否以监测替代辅助化疗:国际多中心分析

Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis.
PubMed 文献 · Eur J Cancer · 2020-08-04

该国际多中心回顾性分析纳入1985年至2018年108例IA-C期纯未成熟畸胎瘤患者,比较术后辅助化疗与监测的结局。监测组与化疗组的恶性复发风险、无病生存和总生存均无显著差异,仅肿瘤分级和完整手术分期为无病生存的独立预后因素。提示经规范分期且术后肿瘤标志物阴性的IA-C期任何级别未成熟畸胎瘤,仔细监测或可替代辅助化疗。

要点

  • IA-C期任何级别未成熟畸胎瘤术后监测与辅助化疗的恶性复发风险无显著差异。
  • 肿瘤分级和完整手术分期是无病生存的独立预后因素。
  • 规范分期且术后肿瘤标志物阴性者,仔细监测或可替代辅助化疗。

核心结论

  • 在成年患者中,经规范分期且术后肿瘤标志物阴性的IA-C期任何级别未成熟畸胎瘤,仔细监测似乎是辅助化疗可接受的替代方案。

研究设计与样本

  • 回顾性分析1985年1月至2018年1月意大利卵巢癌多中心试验中心和英国Charing Cross医院的青春期后IA-C期纯未成熟畸胎瘤患者临床病理资料。

主要发现

  • 108例IA期患者中,FIGO IA、IB、IC期分别占66例(61.1%)、3例(2.8%)、39例(36.1%),G1、G2、G3级分别占31例(28.7%)、41例(38%)、36例(33.3%)。
  • 术后27例(25%)接受辅助化疗,81例(75%)接受监测;监测组与化疗组恶性(G2-3未成熟畸胎瘤)复发风险无显著增加(9/81 vs 2/27;p=0.72),无病生存和总生存亦无显著差异。
  • 中位复发时间17.8个月(范围3-47),监测组与化疗组间无显著差异;中位随访64.3个月(IQR 22.2-101.7)。
  • 化疗使除一例因妊娠未遵循监测方案并死于疾病者外的所有患者获得治愈。
  • 单因素和多因素分析显示,仅肿瘤分级(HR=3.11;p=0.02)和完整手术分期(HR=0.2;p=0.01)是无病生存降低的独立预后因素。

临床怎么用

  • 对经规范分期且术后肿瘤标志物阴性的IA-C期任何级别未成熟畸胎瘤成年患者,可考虑以仔细监测替代辅助化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of surveillance after surgery for stage IA-C grade 2 (G2) or grade 3 (G3) immature teratomas (ITs) is controversial with many guidelines advocating adjuvant chemotherapy. Here, we investigate the safety of surveillance in stage IA-C G1-3 ITs. METHODS: Clinicopathological data were analysed on postpubertal patients with stage I pure ITs in Multicenter Italian Trials in Ovarian Cancer centres and at Charing Cross Hospital, UK, between January 1985 and January 2018. RESULTS: Of 108 stage I patients, 66 (61.1%), 3 (2.8%) and 39 (36.1%) were International Federation of Gynecology and Obstetrics IA, IB, IC, respectively, with 31 (28.7%), 41 (38%) and 36 (33.3%) having grade 1 (G1), 2 and 3 disease, respectively. After surgery, 27 patients (25%) had adjuvant chemotherapy and 81 (75%) surveillance. There was no significant increase in the risk of malignant (G2-3 IT) relapse (9/81 vs 2/27; p = 0.72) or in disease-free survival (DFS) or overall survival in the surveillance vs chemotherapy groups. The median time to relapse was 17.8 months (range: 3-47) with no significant difference between surveillance or chemotherapy groups. The median follow-up was 64.3 months (Interquartile range (IQR) 22.2-101.7). Chemotherapy induced cures in all except for one patient who did not follow the surveillance protocol due to pregnancy and died of disease. Univariate and multivariate analyses revealed that only tumour grade (hazard ratio [HR] = 3.11; p = 0.02) and complete surgical staging (HR = 0.2; p = 0.01) were independent prognostic factors for decreased DFS. CONCLUSION: The present study suggests that in the adult setting careful surveillance appears to be an acceptable alternative to adjuvant chemotherapy for stage IA-C ITs of any grade, properly staged and with negative postoperative tumour markers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bergamini A, Sarwar N, Ferrandina G, et al. Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis. Eur J Cancer. 2020. PMID: 32763784. doi:10.1016/j.ejca.2020.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。